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Gamma scintigraphyAbstract Inhalational drugs often suffer from low pulmonary deposition due to their micronized
size. Aim of present study was development and evaluation of a novel submicronic L-arginine
respiratory ﬂuid formulation for treatment of cardiopulmonary complications associated with
chronic obstructive pulmonary disorder (COPD). Objectives were (a) to develop and characterize
submicronic L-arginine respiratory ﬂuid formulation, (b) pre-clinical safety/toxicity study in 2-ani-
mal species, (c) in vitro and in vivo evaluation in terms of respiratory fraction, and (d) clinical study
to assess safety/efﬁcacy in healthy volunteers/COPD patients. Formulation was optimized on the
basis of particle size of aerosolized medication with particle size in the range of 400–500 nm.
Anderson cascade impaction (ACI) studies were performed to validate the advantage in terms of
respirable fraction, which indicated a high respirable fraction (51.61 ± 3.28) for the developed
formulation. In vivo pulmonary deposition pattern of optimized formulation was studied using
gamma scintigraphy in human volunteers using 99mTc-arginine as radiotracer. It clearly demon-
strated a signiﬁcant pulmonary deposition of the submicronic formulation in various lung compart-
ments. Efﬁcacy of the developed formulation was further assessed in COPD patients (n= 15) by
evaluating its effect on various cardiopulmonary parameters (spirometry, pulse-oxymetry, echocar-
diography and 6-min walk test). A marked improvement was seen in patients after inhalation of
50 V.P.S. Rathor et al.submicronic arginine in terms of their cardiopulmonary status. Results suggest that submicronic
arginine respiratory ﬂuid has the potential to be developed into an attractive therapeutic option
for treating COPD associated cardiopulmonary complications.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is a prominent
but unrecognized cause of morbidity and mortality globally
and is estimated to be the third leading cause of death world-
wide by 2020 (Murray and Lopez, 1997; Pauwels and Rabe,
2004). COPD is characterized by airﬂow obstruction and vari-
ous symptoms such as chronic cough, expectoration, exertional
dyspnea and wheezing (Rennard, 1998). It is also associated
with inﬂammatory process which affects the respiratory tract
up to smaller peripheral airways, which are<2 mm in diameter
(Berge et al., 2011). These smaller airways play a signiﬁcant role
in pathogenesis of the disease and subsequently during any
therapeutic intervention (Burgel, 2011). Progression of disease
leads to deterioration of pulmonary function and the risk of
alveolar hypoxia increases causing vasoconstriction in the
pulmonary circulation and a transient increase in pulmonary
vascular resistance (PVR) (Elwing and Panos, 2008; Rabe
et al., 2007). These changes are observed even in mild COPD
(Santos et al., 2002). Inhaled short-acting ß2-agonists such as
salbutamol sulfate and others are suggested for the acute relief
of airway obstruction and exercise associated bronchospasm.
These drugs are generally inhaled via nebulization or metered
dose inhaler or dry powder inhalation. However, being micro-
nized particles, a lot of drug is wasted in each of these processes
because the preferred site of drug deposition is pharynx and
stomach, followed by trachea-bronchial system, and not
alveoli. This results in suboptimal delivery to the lungs thereby
compromising the therapeutic outcome (Labiris and Dolovich,
2003; O’Callaghan and Barry, 1997).
Deposition of aerosolized drugs inside lungs depends upon
many factors such as the size of the aerosol particles, breathing
conditions, the geometry of airways, and the mucociliary clear-
ance mechanisms (Tena and Clara, 2012). It is well recognized
now that inhaled therapeutic agents should be able to reach up
to the lower airways to obtain maximum therapeutic effect.
This is possible by small sized aerosol particle, preferably
submicron sized, which tend to travel farther and settle in
the deeper compartments of lungs (Capstick and Clifton,
2012; Wedaa et al., 2004). Thus in the management of respira-
tory diseases like COPD, one of the recent strategies has been
reduction of drug particles size to enhance penetrability so that
the drug could be targeted to the desired area in pharmacologi-
cal dose (Wedaa et al., 2004). This approach has been success-
fully used in our laboratory for the development of various
novel inhalational formulations for different clinical indica-
tions (Ali et al., 2013, 2009; Bhavna et al., 2009; Kumar
et al., 2011; Sultana et al., 2014, 2011).
Various preclinical studies have demonstrated the
advantage of short or long-term nitric oxide (NO) inhalation
in pulmonary hypertension and COPD models (Jiang et al.,
2004, 2002; Yoshida et al., 1997; Katayama et al., 1994).
Inhalation of NO mediated formulations such as L-arginine,sodium nitrite and others have been shown to have bron-
chodilator action (Dupuy et al., 1992; Ho¨gman et al., 1993;
Kacmarek et al., 1996; Sapienza et al., 1998; Chambers and
Ayres, 2001; Grasemann et al., 2013). Keeping these effects
of NO donors, including L-arginine in mind, present study
was designed so as to explore the advantage of nanosizing
along with known bronchodilator effect of L-arginine for the
treatment of patients of COPD, with particular reference to
improvement in their cardiopulmonary parameters.
We here report the development, in vitro and in vivo
characterization of a novel submicronic respiratory formula-
tion of L-arginine hydrochloride. Aim was to prepare submi-
cron sized arginine particles in the range of 400–500 nm and
to evaluate the effect of short-term treatment on various car-
diopulmonary parameters (spirometry, echocardiography,
pulse oxymetry, and 6-min walk test) in COPD patients.
Unit dose for nebulization was kept at 1.25% on the basis of
preliminary proof-of-concept studies in human volunteers
and previously reported work on L-arginine (Grasemann
et al., 2013; Sapienza et al., 1998). Another highlight is the
use of gamma scintigraphy to generate real time in vivo data
with respect to total and regional drug deposition pattern in
lungs, a technique which has previously been used in develop-
ing various other drug formulations from our laboratory (Ali
et al., 2009; Bhavna et al., 2009; Rajpal et al., 2009, 2010).
2. Materials and methods
L-arginine hydrochloride and stannous chloride dihydrate
(SnCl2ÆH2O) were procured from Sigma–Aldrich Chemical
Company, St. Louis, MO, USA. All other chemicals used were
of analytical grade purchased from Merck India Ltd.
(Mumbai, India). Technetium-99m (Tc-99m) was supplied by
BRIT, BARC (India).
2.1. Preparation of test formulation
Three milliliter solution of 1.25% L-arginine in normal saline
or in different concentrations of ethanol–saline (10–50%) was
taken as the potential test formulation. Ethanol was added to
produce aerosol particles and to increase the rate of drug
output (Sultana et al., 2011). In vitro nebulization rate and
nebulization fraction of these prospective test formulations
were determined by a standardized and previously reported
method from our laboratory (Mittal et al., 2010). A laser par-
ticle size analyzer (Lasair II, Particle size measuring systems
Inc, USA) was used to estimate the Mass Median Aerosol
Diameter (MMAD) with respect to, (a) 1.25% L-arginine in
saline, (b) preparations containing different concentrations of
ethanol, and (c) chosen test formulation aerosols passed
through a large-volume spacer. For all further experiments,
the chosen test formulation was dispensed in sealed sterile vials
after passing through 0.22 lm ﬁlter.
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Though arginine has been given through inhalation route
earlier, no arginine respiratory formulation is available in com-
bination with ethanol. Keeping this in mind, an acute animal
toxicity study was performed for assessing the local effect of
arginine respiratory formulation on lungs. The study was car-
ried out in two animal species as per Schedule ‘Y’ guidelines of
the Indian Council for Medical Research (ICMR). The animal
experiments were approved by Institute’s Animal Ethical
Committee (INM/IAEC/2007/IX). Sprague Dawley rats (2–
3 months; 200–250 g) and New Zealand white rabbits (1.5–
2 years; 2–2.25 kg) from Institute’s Experimental Animal
Facility were used for the study. The animals were given free
access to standard laboratory animal feed (Golden Feed
Laboratory, Delhi, India) and water ad libitum. As per the
experimental guidelines, three incremental doses (1.25%,
2.5% and 5%) of the test formulation, including the intended
therapeutic dose were inhaled to different groups of animals
(n= 6) using an animal inhalation chamber. Animals were
nebulized twice in a day for seven weeks and monitored daily
with respect to general health, food intake, water consump-
tion, and for any morphological changes in cardio-respiratory
system (short/fast breathing, restlessness, sluggishness). At the
end of the study, animals were sacriﬁced and any histopatho-
logical changes in lungs and other vital organs of test animals
were compared with those of controls.
2.3. In vitro estimation of respiratory fraction
In vitro estimation of respiratory fraction was carried out using
Anderson Cascade Impactor (ACI) (Copley Scientiﬁc,
Nottingham, UK), which consisted of an initiation port (IP),
pre-separator (PS), seven stages and a ﬁnal collection ﬁlter.
Based on the results of formulation optimization study men-
tioned above, 3 mL of selected test arginine formulation was
nebulized by jet nebulizer (American Bantex Corp., Alphaneb
Plus nebulizer, NJ, USA) through a spacer that was in turn
connected to initiation port of the ACI. Nebulization was per-
formed for 10 min and the wash solutions from initiation port,
pre-separator deposit, and various stages of ACI were collected
and quantiﬁed for drug content by high-performance liquid
chromatography (Quaternary HPLC system, Shimadzu,
Japan). Respirable fraction was calculated as the ratio of per-
centage of total drug deposited in the lower stages of the ACI
(stage 1 to ﬁlter) to total theoretical dose, describing the per-
centage of aerosolized drug deposited deeply into the lungs.
2.4. Clinical study
The study protocol was approved by the Institutional Human
Ethics Committee, duly constituted for the purpose (INM/TS/
IEC/013/07). The clinical study was performed in the following
sequential manner: (a) safety study and evaluation of
pulmonary drug deposition pattern of the developed formula-
tion using gamma scintigraphy in healthy volunteers (n= 6;
mean age 26.6 ± 4.7 years), (b) limited efﬁcacy study in 15
chronic obstructive airway disease patients (n= 15; mean age
51.5 ± 8.2 years) followed by gamma scintigraphy study as
mentioned above. The patients belonged to the outpatient
department of Rajanbabu Institute of Pulmonary Medicineand Tuberculosis, Delhi with documented diagnosis of COPD.
Patients having prior hypersensitivity to arginine or critically
sick patients or those having mixed disease pattern, or those
likely to develop severe grade of dyspnea, children and pregnant
females were excluded from the study. All participants gave
their written informed consent for participation in the study.
2.4.1. Gamma scintigraphic study
For in vivo pulmonary evaluation to ascertain total and
regional lung deposition of nebulized arginine by gamma
scintigraphic method, the drug was radiolabeled with Tc-99m
using stannous based reduction protocol reported previously
(Gulati et al., 2005). Radiolabeling efﬁciency and stability of
Tc-99m radiolabeled arginine (99mTc-arginine) were deter-
mined by standard procedures involving instant thin layer
chromatography (ITLC) and a gamma counter (Capintec,
USA) (Sultana et al., 2011; Singh et al., 2007). Nebulization
rate of un-labeled and Tc-99m radiolabeled arginine (analyzed
by HPLC and radiometry respectively) was correlated to
establish bio-equivalence between the two methods.
Gamma scintigraphy study was carried out using a dual
head gamma camera system (Symbia T2, Siemens, Erlangen,
Germany). Based on the results of formulation optimization
study mentioned in previous section, 3 mL of selected test argi-
nine formulation containing tracer quantity of 99mTc-arginine
was nebulized through a spacer to the volunteers. Following
inhalation, two dimensional scintigraphy images of the chest
region were acquired within 5 min of inhalation covering
oropharynx to stomach. All images were recorded on a com-
puter system assisted with the software (Syngo, Siemens,
Erlangen, Germany). Additional images of the chest region
were taken at 30 min and 60 min to observe the movement
of the drug. Regions of interest were drawn around the
oropharynx, esophagus, stomach and whole lung for obtaining
count statics. The counts within these regions were corrected
for background radioactivity, radioactive decay and tissue
attenuation of gamma rays (Pitcairn and Newman, 1997).
The lung region was further sub-divided into central,
intermediate and peripheral sections, representing mainly the
respiratory tree, mixed and alveolar region respectively
(Newman et al., 1989). Lung images were also visually com-
pared to observe movement of the deposited radiolabeled drug
particles with time from one compartment to another.
2.4.2. Limited efﬁcacy study in COPD patients
The study was carried out in 15 COPD patients. On the ﬁrst visit
their baseline parameters were ascertained, followed by nebu-
lization of 3 mLof submicronic arginine respiratory formulation
thrice a day for next four days. Spirometry (Portable Mir
Spirometer; Spiro Lab III, Italy), pulse-oxymetry (Planet-40,
Larsen and Toubro Limited, India), echocardiography
(VIVID-7 model, GE Healthcare System, Germany) and 6-min
walk test were performed on patients before and at the end of
the study to assess the effect on their cardiopulmonary status.
2.5. Statistical analysis
Data were presented as mean ± S.D. Paired student’s t-test
was applied for the calculation of signiﬁcance at p< 0.05
using GraphPad Instat version 3.00 for Windows XP,
GraphPad Software, San Diego, CA.
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The present study describes optimization of a novel submicro-
nic 1.25% arginine hydrochloride respiratory formulation; its
in vitro and in vivo characterization; gamma scintigraphy
based evaluation of drug’s pulmonary deposition pattern;
and clinical study to evaluate its effect on various cardiopul-
monary parameters in COPD patients.
3.1. Optimization of test formulation
Table 1 depicts the correlation between nebulization patterns
of 99mTc-labeled arginine and un-labeled arginine. Results
show a good correlation between their nebulization patterns,
corroborating the results previously reported from our
laboratory (Mittal et al., 2010) and validating radiometry as
a suitable technique for estimating amount of arginine nebu-
lized or deposited in various compartments. For this, arginine
hydrochloride was ﬁrstly radiolabeled with Tc-99m using
already established stannous based reduction protocol
(Gulati et al., 2005). The drug was successfully radiolabeled
(99mTc-arginine) with a high radiolabeling efﬁciency of
>96%. Serum stability studies showed 93% and 90%
radiolabeling efﬁciency of arginine after 6 and 24 h respec-
tively, indicating the stability of labeled drug.
Nebulization rates and nebulized fraction of potential
arginine formulations are shown in Table 2. Results show that
nebulization rate as well as the nebulized fraction for arginine
respiratory ﬂuid was maximum when 30% ethanol–saline was
used in the formulation for nebulization. Particle size analysis
done through laser particle size analyzer (Lasair II, Particle
size measuring systems Inc, USA) revealed the following
MMAD: (a) control formulation (1.25% arginine in normal
saline): 7.9 ± 0.5 lm, (b) different arginine-ethanolic salineTable 1 Bio-equivalence data between arginine and 99mTc-
arginine nebulization rates at different intervals (n= 6).
Time 99mTc-arginine in
nebulization chamber (%)
Arginine in
nebulization chamber
(%)
0 min 100 100
5 min 78.4 ± 4 79.5 ± 3.3
10 min 72.6 ± 2.8 71.8 ± 3.0
20 min
(after
drying)
65.8 ± 2.6 65.1 ± 2.5
Correlation value (r) = 0.902.
Table 2 Effect of varying concentration of ethanol–saline on neb
(n= 6).
Ethyl alcohol–saline (%)
0 10 2
Nebulization rate/min
1st min 4.8 ± 0.8% 5.0 ± 0.6% 6
10th min 4.3 ± 0.5% 4.2 ± 0.4% 5
15th min 4.1 ± 0.5% 4.1 ± 0.2% D
Nebulized fraction (%) 29.6 ± 3.5 37.2 ± 4.4 5preparations containing 10%, 20%, 30%, 40% or 50% etha-
nol: 4.8 ± 0.6 lm, 3.6 ± 0.5 lm, 1.6 ± 0.3 lm, 1.5 ± 0.2 lm
and 1.1 ± 0.2 lm respectively, and (c) chosen test formulation
(1.25% arginine in 30% ethanol–saline) passing through
spacer: 0.44 ± 0.1 lm.
On the basis of the results obtained, which corroborated
with previous reports of use of 30% ethanol–saline in
respiratory ﬂuids (Sultana et al., 2011), 1.25% arginine in
30% ethanol–saline to be nebulized through a spacer was cho-
sen as the ﬁnal formulation.
Large spacers attached in series to any standard nebulizer
assembly are known to impart a few advantages over conven-
tional nebulization, like generation of smaller sized particles
for inhalation and less wastage of drug aerosols to surrounding
environment (Mittal et al., 2010). It is well accepted that reduc-
tion in drug aerosol size leads to deeper penetration of the
medication into the lungs (Finlay et al., 1997; Hadinoto
et al., 2007; Hoet et al., 2004). However, submicronic aerosols
tend to be exhaled back, resulting in sub-optimal use of
nano-inhalation therapy in clinical settings. This problem
was circumvented by using ethanol, which has been used ear-
lier for producing vaporized drug particles for inhalation and
retaining them within the lung microvasculature (Sultana
et al., 2011). Gamma scintigraphy done with 99mTc radiola-
beled arginine-ethanol saline formulation showed signiﬁcant
delivery and deposition of the submicronic drug in alveolar
spaces. Clinical results of this study support the in vitro and
scintigraphy observations.
3.2. Preclinical toxicity study
Experimental animals exposed to inhalation of arginine
respiratory ﬂuid in three incremental doses (1.25%, 2.5%
and 5%) did not exhibit any biochemical or behavioral
changes. Histopathology of vital organs revealed no gross
changes with respect to their weight or general morphology.
Fig. 1 shows microphotographs of the lungs in control and test
animals exposed to highest arginine concentration (5%). No
local pulmonary toxicity was seen except for some congested
microcirculation within the lung microvasculature.
3.3. In vitro estimation of respiratory fraction
Fig. 2 represents the ACI results (% drug deposition pattern)
of novel submicronic 1.25% arginine in 30% ethanol–saline
respiratory formulation. The formulation had a high respirable
fraction of 51.61 ± 3.28. The respirable fraction was calcu-
lated as the ratio of total drug deposited in lower stages of
the ACI (stage 1 to ﬁlter) to total theoretical dose, and it is aulization rate/min and nebulized fraction using 99mTc-arginine
0 30 40 50
.2 ± 0.8% 8.8 ± 1.0% 8.0 ± 0.8% 6.4 ± 0.5%
.4 ± 0.6% 8.2 ± 0.6% 7.5 ± 0.6% 6.1 ± 0.5%
ry Dry Dry Dry
5.3 ± 6.5 68.6 ± 5.8 68.3 ± 6.5 69.3 ± 7.5
Table 3 In vivo gamma scintigraphic evaluation of total and
regional pulmonary deposition of submicronic L-arginine
aerosols after inhalation of 99mTc-arginine respiratory ﬂuid.
Variables Drug deposition (%
radioactivity)
No. of subjects 6
Nebulizer cup 48 ± 4
Spacer, mouthpiece and T-piece 11 ± 1
Exhalation ﬁlter 19 ± 1
Emitted dose 22 ± 2
Oropharynx, esophagus and
stomach
7 ± 2
Whole lung 15 ± 2
a) Central a) 5 ± 0.6
b) Intermediate b) 6 ± 0.8
c) Peripheral c) 4 ± 0.5
P/C ratio 0.8
Data are presented as mean ± S.D.
Whole-lung deposition is the sum of central, intermediate, and
peripheral values.
Figure 1 Comparison of lung micrograph of (A) control and (B) treatment group rabbit nebulized with submicronic 5% arginine in 30%
ethanol–saline (four times the intended human pharmacological dose) twice a day for 7 weeks showing no apparent hemorrhage or edema
in the tissue in both cases. (H.E. · 20 magniﬁcation).
Figure 2 ACI study comparison for percentage deposition in each stage for submicronic arginine respiratory ﬂuid (nebulization
time = 10 min; n= 6).
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lungs (Mittal et al., 2014).
3.4. Clinical study
3.4.1. Gamma scintigraphic study
Table 3 shows quantitative data using gamma scintigraphy
with respect to relative percentage of the inhaled drug (a)
deposited in different lung compartments of a human volun-
teer, (b) amount retained in oropharynx, and (c) amount
remaining in nebulizer assembly. Although nearly 78% of
the drug was retained in nebulizer assembly at the end of nebu-
lization, two-third of the inhaled portion reached the lungs,
resulting in a high respirable fraction for the nebulized drug.
Whole lung deposition was in the range of 15 ± 2%, while
only 7 ± 2% of the nebulized drug was deposited in orophar-
ynx compartment, representing oropharynx, esophagus and
stomach. It is much less in comparison with that reported
for micronized drugs, where nearly two-third of the drug is
deposited in the oral region and is not available to the lungs
(Bhavna et al., 2009). The ratio of peripheral to central lung
zone deposition for submicronic arginine respiratory ﬂuid
was 0.8.
Visual examination of the lung scintigraphy scans showed
an appreciably deep lung penetration of the submicronic drug,
with majority of the drug being deposited in central and
peripheral regions and less accumulation in oropharynx,trachea, esophagus and stomach at 5, 30 and 60 min intervals
(Fig. 3A). In case of COPD patients, similar observations
were made although their lung uptake was obviously much less
Figure 3 Gamma scintigraphy showing in vivo pulmonary deposition pattern of submicronic 1.25% arginine respiratory formulation in
(A) healthy volunteer, (B) COPD patient, showing distribution of the drug at 5, 30 and 60 min after inhalation.
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(Fig. 3B).
3.4.2. Limited efﬁcacy study in COPD patients
It may be reasoned that elevated lung deposition, associated
with more absorption through alveoli may cause higher sys-
temic effects and therefore an increased risk/beneﬁt ratio.
Therefore, serial measurements of respiratory functions, heart
rate, SPO2, mPAP and 6-min walk test were used to assess the
immediate effects of submicronic arginine inhalation in
healthy/diseased subjects. No signiﬁcant change in physiologi-
cal parameters was seen in healthy volunteers after inhalation
of the test formulation, conﬁrming its safety.
Any beneﬁcial effect after inhalation of submicronic
arginine respiratory formulation with respect to their car-
diopulmonary status was studied in 15 COPD patients. The
results are depicted in Fig. 4. There was a signiﬁcant change
in SPO2 levels and heart rate (p< 0.05) before and at the
end of 4-day treatment period. There was also a signiﬁcant
improvement in subjects’ mean pulmonary artery pressure
(mPAP) before (27.91 ± 2.75 mmHg) and after
(25.7 ± 4.78 mmHg) the treatment. Spirometry parameters
such as FEV1 (Forced expiratory volume in 1 s) and FVC
(Forced vital capacity) also improved in all the subjects at
the end of 4-day study period (48.3 ± 10.88% and
63.53 ± 9.13% of predicted respectively) as compared to at
the beginning (45.2 ± 10.98% and 60.13 ± 6.22% of pre-
dicted respectively). In 6-min walk test the average distance
covered by patients at the start of study was 395 ± 53.88 m.
Post-treatment, the patients were able to walk an average dis-
tance of 437.7 ± 66.28 m. Thus, all the subjects were able to
show a marked improvement in their cardiopulmonary statusat the end of 4-day study period. Furthermore, no side effects
or any kind of discomfort was reported by the volunteers and
in general the patient acceptability was quite good. Subjective
relief was reported by nearly 90% of the 15 COPD patients.
Arginine is a precursor of NO and inhalation of NO has been
shown to reduce PAP, besides improving exercise tolerance
and oxygenation (Perez-Penate et al., 2001; Vonbank et al.,
2003; Yung et al., 2001). These reports validate the ﬁndings
of our study, which strongly suggest advantage of submicronic
arginine nebulization in improving cardiopulmonary com-
plications in COPD and/or other respiratory condition.
Gamma scintigraphy has been widely used to assess pul-
monary deposition of inhaled drugs (Ali et al., 2013, 2009;
Bhavna et al., 2009; Kumar et al., 2011; Sultana et al.,
2014). Our results suggest a high deposition of submicronized
arginine particles in various regions of lung, a pattern which
was observed till the period for which the scintigraphy study
was conducted. Moreover, a lower oropharyngeal deposition
seen with this formulation may also negate the disadvantage
of systemic side-effects like tachycardia and tendency of
esophagitis associated with presently available options like
micronized salbutamol inhalation. The results suggest submi-
cron sized arginine formulation can ensure a high local avail-
ability of the drug in the lungs. The probable reason for this
could be that submicron sized particles are largely spared from
undergoing phagocytosis by macrophages stationed in the
respiratory tract, while the larger micronized particles readily
undergo phagocytosis (Edwards et al., 1998; Fels and Cohn,
1986; Oberdorster et al., 2005). Since number of macrophages
is too high in case of airway diseases such as COPD and
asthma, this may cause suboptimal pharmacological action
of micronized drug particles in comparison with submicron
Figure 4 Effect of submicronic L-arginine inhalation on cardiopulmonary status of COPD patients [FVC-Forced vital capacity, FEV1-
Forced expiratory volume in 1st second, mPAP-mean pulmonary artery pressure; data presented as mean ± S.D.; * indicates signiﬁcant
difference (p< 0.05) between values measured before and after treatment in patients with cardiopulmonary complications].
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released from the macrophages eventually, but their concentra-
tion at that time would be suboptimal for any clinical beneﬁts.
Another advantage of submicronic formulation is that smaller
particles deposit more in peripheral lungs and from there move
toward the center by mucociliary action resulting in sustained
action of the drug. Respiratory diseases such as COPD and
asthma are characterized by airway inﬂammation and
increased mucus production, which leads to further narrowing
of the airways with low drug delivery and less bioavailability in
lungs. Smaller particles are more likely to pass through these
constricted airways in comparison with larger particles result-
ing in their greater bioavailability.4. Conclusion
Results of the present study suggest that submicronic 1.25%
arginine in 30% ethanol–saline respiratory formulation may
be developed into a potential therapeutic option in treating
bronchopulmonary diseases such as COPD. Further clinical
studies with larger sample size are however required to conﬁrm
the efﬁcacy of the test formulation.References
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